All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

PD-L1 and PD-1 Expression in Thyroid Follicular Epithelial Dysplasia: Hashimoto Thyroiditis Related Atypia and Potential Papillary Carcinoma Precursor

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F22%3A10441407" target="_blank" >RIV/00064203:_____/22:10441407 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11110/22:10441407 RIV/00216208:11140/22:10441407

  • Result on the web

    <a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=lMYqOubbCY" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=lMYqOubbCY</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1111/apm.13218" target="_blank" >10.1111/apm.13218</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    PD-L1 and PD-1 Expression in Thyroid Follicular Epithelial Dysplasia: Hashimoto Thyroiditis Related Atypia and Potential Papillary Carcinoma Precursor

  • Original language description

    PD-L1 and PD-1 Expression in Thyroid Follicular Epithelial Dysplasia: Hashimoto Thyroiditis Related Atypia and Potential Papillary Carcinoma Precursor Programmed cell death ligand (PD-L1)/PD-1 expression has been studied in a variety of cancers and blockage of PD-L1/PD-1 pathway is a cornerstone of immunotherapy. We studied PD-L1/PD-1 immunohistochemical expression in 47 thyroid gland specimens in groups of 1) Hashimoto thyroiditis (HT) only, 2) HT and follicular epithelial dysplasia (FED) and 3) HT, FED and papillary thyroid carcinoma (PTC). PD-1 positivity was found in immune cells, namely in lymphocytes, macrophages, and plasma cells with mean values for lymphocytes and macrophages 9% in HT group, 4% in FED group, and 4% in PTC group. PD-L1 positivity was identified in both immune cells and in the normal epithelial cells. In the HT group, mean PD-L1 staining on immune cells was 6%, in FED group 5%, and in PTC group 7%. The mean PD-L1 staining on the epithelial cells in the inflammatory parenchyma was 11.7% in HT, 13.4% in FED and 8.3% in PTC group. The mean PD-L1 staining of FED foci was 47.2% in FED group and 33.6% in PTC group. The mean tumor proportion score (TPS) was 10.4% and the mean combined positive score (CPS) was 15.5. At the moment, PTC is not a target of immunotherapy. However, understanding the complex issue of concurrent inflammation and autoimmunity can importantly influence the cancer treatment in future.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30206 - Otorhinolaryngology

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2022

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    APMIS

  • ISSN

    0903-4641

  • e-ISSN

    1600-0463

  • Volume of the periodical

    130

  • Issue of the periodical within the volume

    5

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    8

  • Pages from-to

    276-283

  • UT code for WoS article

    000767947700001

  • EID of the result in the Scopus database

    2-s2.0-85126084752